Ellodi Pharmaceuticals

Ellodi Pharmaceuticals is a biopharmaceutical company headquartered in Blue Bell, PA, United States. The company is focused on developing innovative therapies for eosinophilic esophagitis, with a pipeline that includes the investigational drug APT-1011 currently in the FLUTE 3 clinical study. Ellodi Pharmaceuticals is committed to collaborating with patient advocacy groups to address the unmet medical needs of individuals affected by this chronic condition.